This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance.
Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.
This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance.
Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.
This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance.
Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.
This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance.
Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.
This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance.
Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.
This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance.
Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.
This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance.
Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.
This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance.
Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.
This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance.
Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.
This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance.
Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.
This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance.
Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.
This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance.
Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.
This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance.
Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.
This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance.
Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.
This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance.
Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.
This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance.
Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.
This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance.
Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.
This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance.
Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.
This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance.
Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.
Awaiting Public Project Summary
Awaiting Public Project Summary